Istesso’s ground-breaking research hits the headlines
Recent press coverage of our work to develop healthspan-extending drugs recognises their potential to offer “a more sustainable path to healthier, longer lives”
4th December 2025Restore Harmony. Extend Healthspan.
Developing first-in-class mitochondrial complex I modulators (MCMs)
Istesso is rethinking how we extend healthspan as we age. Rather than trying to stop or slow disease progression, we focus on restoring the body’s natural capacity to repair itself and return to health.
Our pioneering approach centers on mitochondrial Complex I modulators, or MCMs, a new class of oral small molecule drugs that repair and regenerate tissue across multiple organs and disease settings. Our lead clinical program, leramistat, is in Phase 2 trials, and we are expanding MCMs to other chronic diseases of aging with a pipeline of assets, each holding blockbuster potential.
"The ability to repair and regenerate damaged tissue offers us the enormous and game-changing potential to rethink how we treat and manage chronic diseases and age-related decline. It’s hard to imagine anything more rewarding and exciting than that"
Latest news
Istesso provides updates on leramistat and next-generation programs
Advancement of leramistat, a first-in-class mitochondrial complex I modulator (MCM),...
26th November 2025
Ground-breaking data demonstrates tissue repair with Istesso’s novel investigational medicines
Istesso’s new class of developmental drugs, which inhibit mitochondrial complex...
17th July 2025